Introduction
============

Ovarian carcinoma (OC) has the highest mortality rate among gynecological and reproductive malignant tumors in the United States. The early symptoms that patients exhibit are not obvious and are nonspecific due to the fact that the ovary lies deep within the pelvic cavity. In addition, OC is often initially diagnosed in an advanced stage due to the lack of effective detection measures. The 5-year survival rate of patients with OC is only 15--40% ([@b1-or-44-03-0909],[@b2-or-44-03-0909]). The primary treatments for advanced epithelial ovarian cancer (AEOC) patients include primary cytoreductive surgery, chemotherapy, radiotherapy and endocrine therapy. In the 1970s, Griffiths and Fuller ([@b3-or-44-03-0909],[@b4-or-44-03-0909]) proposed neoadjuvant chemotherapy (NACT) as an alternative treatment for AEOC patients. The aim of NACT is to improve the preoperative status of patients, reduce the tumor volume and post-surgical complications, create conditions that allow surgery, and improve the quality of life and prognosis of the patient. However, when eliminating tissue plane, NACT can promote inflammatory adhesion, which complicates surgery in a small number of AEOC patients. Moreover, NACT can induce resistance to platinum-based chemotherapies in tumor cells by exposing large tumor volumes to chemotherapy ([@b5-or-44-03-0909]). To date, there is no uniform standard for accurately evaluating and screening OC patients to determine their suitability for NACT. Currently, the common evaluation methods used internationally by gynecological oncologists include cancer antigen 125 (CA125), human epididymis protein 4 (HE~4~), computed tomography (CT), MRI and laparoscopic exploration ([@b6-or-44-03-0909]--[@b8-or-44-03-0909]). However, any single method mentioned above is not ideal enough to screen for patients indicative for NACT ([@b9-or-44-03-0909]). There is an urgent need for a novel biological predictor that can facilitate the selection of patients suitable for NACT. Consequently, to maximize the therapeutic effect of NACT and avoid tumor cell resistance caused by the overuse of NACT, biomarkers are needed to screen the most suitable ovarian cancer patients for NACT and to enable therapy targeted at the process of platinum-based chemoresistance at the molecular level. Simultaneously, it is important to elucidate the resistance mechanisms of tumor cells to chemotherapeutic drugs and to attempt to reverse their resistance.

The present study was based on NACT and drug-resistant microarrays from the GEO database. We identified four differentially expressed genes (DEGs) associated with NACT and chemoresistance in AEOC. Therefore, these core genes may be potential therapeutic targets for NACT and platinum-based chemoresistance factors as well as candidate biomarkers in AEOC.

Materials and methods
=====================

### Microarray data

Three eligible profiles (GSE114206, GSE41499 and GSE33482) of drug resistance and one gene expression profiles (GSE109934) of NACT were obtained from the GEO databases (<http://www.ncbi.nlm.nih.gov/geo/>) ([@b10-or-44-03-0909],[@b11-or-44-03-0909]).

### Identification of DEGs

GEO2R is an interactive web tool that identifies differentially expressed genes (DEGs) by comparing two sets of samples that belong to the GEO database ([@b12-or-44-03-0909]). Platinum-sensitive OC samples were compared with platinum-resistant samples by GEO2R. Platinum sensitivity was defined by a complete response during adjuvant chemotherapy and clinical remission for at least 6 months after the completion of chemotherapy. Platinum resistance was defined as progressive or persistent disease or progression within 6 months of completing platinum therapy. The pre-NACT OC samples and the post-NACT samples of the GSE109934 profile were divided into a platinum-sensitive group and platinum-resistant group. The pre-NACT OC samples were compared with the post-NACT samples using GEO2R. The defining values used to screen out statistically significant DEGs were \|log FC\| ≥1 and P\<0.05. As a followed up, we visually displayed the DEGs in the form of heat maps using Morpheus ([https://software.broadin stitute.org/morpheus/](https://software.broadin stitute.org/morpheus/)) online tools. To screen for DEGs that were more likely to be associated with neoadjuvant chemotherapy and platinum-based chemotherapy resistance, we used a Venn diagram to filter the results. In addition, the patient clinical information of the microarray profiles GSE114206, GSE41499, GSE33482, and GSE109934, including the demographic features, FIGO stage, and histological type as well as grade were listed.

### GO and KEGG analyses of DEGs

To understand the nature of the DEGs, we determined their biomolecular functions via their Gene Ontology (GO) annotations. To better understand gene and protein functions, we used the Metascape (<http://metascape.org/>) online tool to analyze the DEGs. One of the hallmarks of the Kyoto Encyclopedia of Genes and Genome (KEGG) database (<http://www.genome.jp/>) is the ability to correlate fully sequenced gene catalogs with higher-level cellular and ecosystem functions. In addition, EasyChart (<http://www.ehbio.com/ImageGP/>) was used to highlight the different signaling pathways associated with gene enrichment. Using the The Database for Annotation, Visualization and Integrated Discovery (DAVID) (<http://david.abcc.ncifcrf.gov/>) online tool ([@b13-or-44-03-0909]) for GO categories and KEGG pathway enrichment analysis, we were able to reveal the roles of these DEGs in the underlying mechanisms of neoadjuvant chemotherapy and platinum-based chemotherapy resistance.

### PPI network construction and module analysis

STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) (<http://string-db.org/>) is a search tool for studying genetic interactions and assessing protein-protein interaction (PPI) through the retrieval of data on interacting genes/proteins ([@b14-or-44-03-0909]). Exploring protein interactions allow us to more fully understand the potential regulatory mechanisms that govern biological processes. Therefore, the visualization analysis software Cytoscape ([@b15-or-44-03-0909]) was used to construct a network and map the underlying relationships among the DEGs.

### Protein/gene interaction network and biological process annotation analyses

GeneMANIA (<http://www.genemania.org/>) ([@b16-or-44-03-0909],[@b17-or-44-03-0909]) is a vast database of genomics and proteomics that can be used to predict gene function and prioritize genes based on a protein/gene interaction network. Coremine Medical ([http://www.coremine.com/medic al/](http://www.coremine.com/medic al/)) is an online tool that can be used to conduct homologous similarity analysis of gene sequence, and consult the biological processes affected via query genes based on ontology language, semantic networks, intelligent analysis and other technical support.

### Variation of the 4 genes in EOC

The cBioPortal (<https://www.cbioportal.org/>) is a comprehensive genetic database that includes data on DNA mutations, gene amplification and methylation. The cBioPortal v1.11.3 visualization and analysis tools were used to summarize the possible genetic variation in 4 abnormally expressed genes in EOC and to further analyze the clinical value of this genetic variation.

### Cell culture

The ovarian cancer cell lines SKOV3, HeyA8 and A2780 were obtained from the University of Texas M.D. Anderson Cancer Center (Houston, TX, USA) via ATCC. The cell lines were continuously subcultured in a moist incubator at 37°C under 5% carbon dioxide in 10% fetal bovine serum (FBS) in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.). We established cisplatin-resistant cell lines, SKOV3-CDDP and HeyA8-CDDP, and carboplatin-resistant cell line, A2780-CBP, by successively increasing the concentrations of cisplatin and carboplatin, respectively, as previously described ([@b18-or-44-03-0909],[@b19-or-44-03-0909]).

### Migration and invasion assays

To assess the migration and invasion potential of the cells *in vitro*, migratory and invasive tests were conducted in Transwell chambers with an aperture of 8 µm (Corning Costar, Inc.). Cells (5×10^4^) were evenly mixed with 100 µl RPMI-1640 medium without serum and transferred to the upper Transwell chamber. After incubation for 24 h, the migratory cells adhering to the sub-membrane surface were fixed (4% paraformaldehyde) and stained for 10 min at room temperature (0.1% crystal violet). For the invasion assay, the bottom of the transfer hole in the upper chamber was covered with Matrigel (BD Bioscience). Each trial was repeated three times. The number of migrating and invading cells in 10 randomly selected areas were counted at ×100 magnification under a microscope (Olympus).

### Quantitative RT-PCR analysis

Using the GoScript™ reverse transcription system (Promega), 1 µg total RNA in TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was reverse transcribed to cDNA based on the manufacturer\'s instructions. The oligonucleotide sequence information used to amplify the target mRNA is shown in [Table I](#tI-or-44-03-0909){ref-type="table"}. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize the level of mRNA expression. The PCR conditions for the reaction were as follows: An initial denaturation step at 95°C for 5 min, followed by 40 cycles of 95°C for 12 sec and 60°C for 30 sec. GoTap qPCR Master Mix kit (Promega) was used to detect the quantity of each target mRNA, and relative expression was calculated using the 2^−ΔΔCq^ method ([@b20-or-44-03-0909]).

### Statistical analysis

GraphPad version 6.0 statistical software (GraphPad Software, Inc.) was used to analyze the experimental data. Student\'s t-test was used to analyze comparisons between groups. Quantitative data are presented as the mean ±SD. All statistics were two-tailed, and P\<0.05 was considered statistically significant.

Results
=======

### Gene expression profiles

Microarray data for the drug-resistant profiles, GSE114206, GSE41499 and GSE33482, and the gene expression profile, GSE109934 for NACT were obtained from GEO. The platforms for these datasets were GPL13497, GPL3921, GPL6480 and GPL19956, respectively. The GSE114206 profile contained 12 samples, including 6 platinum-resistant samples and 6 platinum-sensitive samples; the GSE41499 profile contained 8 samples, including 4 platinum-resistant samples and 4 platinum-sensitive samples, and the GSE33482 profile contained 12 samples, including 6 cisplatin-resistant samples and 6 cisplatin-sensitive samples. The GSE109934 profile consisted of 38 samples (a total of 19 patients; each patient provided a tissue sample before and after NACT), including 19 pre-NACT samples and 19 post-NACT samples, and finally each received 2--6 cycles of chemotherapy before surgery and 9 of these were classified as platinum resistant and 10 cases classified as platinum sensitive. A series of matrix files were downloaded as TXT files. Data preprocessing included the conversion and rejection of unqualified data, calibration, filing of missing data and standardization. The demographics and clinical characteristics of these samples of the microarray profiles GSE114206, GSE41499 and GSE109934, except for the GSE33482 profile are summarized in [Tables SI](#SD1-or-44-03-0909){ref-type="supplementary-material"} and [SII](#SD1-or-44-03-0909){ref-type="supplementary-material"}.

### DEG screening

A comparison of the chemotherapy-sensitive samples and the chemotherapy-resistant samples identified the DEGs based on GEO2R analysis and the defined values of \|log FC\| ≥1 and P\<0.05. A total of 1,976, 1,086 and 3,382 DEGs were identified from the GSE114206, GSE41499 and GSE33482 datasets, respectively (expression heat map of the top DEGs are shown in [Fig. 1A-C](#f1-or-44-03-0909){ref-type="fig"} from GSE114206, GSE33482 and GSE41499). A total of 63 genes were selected as DEGs from the GSE109934 profile by comparing the platinum-resistant group with the platinum-sensitive group, and the two groups both contained pre-NACT samples with post-NACT samples. The expression heat maps are shown in [Fig. 1D](#f1-or-44-03-0909){ref-type="fig"}. Of these DEGs, 1,040 upregulated and 936 downregulated genes were selected from GSE114206, and 536 upregulated and 550 downregulated genes were selected from GSE41499. Subsequently, 106 DEGs from the two datasets (GSE114206 and GSE41499) were selected, of which 36 genes were upregulated and 70 genes were downregulated ([Fig. 2A](#f2-or-44-03-0909){ref-type="fig"}). A total of 2,052 upregulated and 1,330 downregulated genes were identified in GSE33482, and 45 upregulated and 18 downregulated genes were identified in GSE109934. Subsequently, 406 DEGs with the same expression pattern as the DEGs of the GSE114206 and GSE33482 datasets were selected, which included 157 upregulated genes and 249 downregulated genes ([Fig. 2B](#f2-or-44-03-0909){ref-type="fig"}). To further screen genes related to drug resistance before and after neoadjuvant chemotherapy, 106 DEGs and 406 DEGs from the drug-resistant profiles were compared with GSE109934 (the NACT profile). The results indicated that two core genes, nuclear factor of activated T-cells, cytoplasmic 1 (*NFATc1*) and Kruppel-like factor 4 (*KLF4*), were potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance ([Fig. 2C](#f2-or-44-03-0909){ref-type="fig"}). Three key genes \[*NFATc1*, nuclear receptor subfamily 4 group A member 3 (*NR4A3*) and hepatocyte growth factor (*HGF*)\] were selected ([Fig. 2D](#f2-or-44-03-0909){ref-type="fig"}). The results of the overall screening are shown in the Venn diagram in [Fig. 2E](#f2-or-44-03-0909){ref-type="fig"}. Four genes potentially associated with NACT and platinum-based chemoresistance were screened, including *NAFTc1, KLF4, NR4A3* and *HGF*.

### GO and KEGG analyses

The results of the GO and KEGG analyses are presented in [Tables II](#tII-or-44-03-0909){ref-type="table"} and [III](#tIII-or-44-03-0909){ref-type="table"}, respectively, based on P\<0.05 in the DAVID tool. Of the 106 DEGs, those that were upregulated DEGs were most abundant in the BP categories 'Negative regulation of signal transduction' and 'Negative regulation of cell communication' as well as MF category 'Transcription regulator activity'. The downregulated DEGs were primarily associated with 'Positive regulation of defense response' in the BP category, 'Plasma membrane part' in the CC category, and 'Cytokine activity' and 'Growth factor activity' in the MF category. Consistent with the results of the KEGG analysis, the downregulated DEGs were enriched in 'Toll-like receptor signaling pathway' development ([Table II](#tII-or-44-03-0909){ref-type="table"}).

Of the 406 DEGs, the upregulated DEGs were principally concentrated in the BP category 'Positive regulation of multicellular organismal process', the CC category 'Extracellular region part', and the MF categories 'Cytokine activity' and 'Carbohydrate binding'. The downregulated DEGs were primarily associated with 'Defense response to a Gram-positive bacterium' in the BP category, 'Extracellular region part' in the CC category, and 'Phosphoric diester hydrolase activity' in the MF category. The results also showed that the upregulated DEGs were generally associated with 'Cytokine-cytokine receptor interaction', 'Type I diabetes mellitus' and 'JAK-STAT signaling pathway', whereas the downregulated DEGs were associated with 'Cell adhesion molecules (CAMs)', 'Cytokine-cytokine receptor interaction' and 'Allograft rejection' according to the KEGG pathway analysis ([Table III](#tIII-or-44-03-0909){ref-type="table"}). The outcomes of the 106 DEGs and 406 DEGs are also presented as a bar chart and scatterplot diagram of the results of the GO and KEGG analyses, respectively. According to the results of a bar chart and scatterplot diagram in 106 DEGs, the significantly enriched GO terms were cytokine-mediated signaling pathway, cytokine biosynthetic process and epidermis development in [Fig. 3A](#f3-or-44-03-0909){ref-type="fig"} and the significantly enriched KEGG terms were Toll-like receptor signaling pathway in [Fig. 3C](#f3-or-44-03-0909){ref-type="fig"}. The results of a bar chart and scatterplot diagram in 406 DEGs showed that GO terms were mainly enriched in the cytokine-mediated signaling pathway, cytokine production and type I diabetes mellitus in [Fig. 3B](#f3-or-44-03-0909){ref-type="fig"} while KEGG terms were mainly enriched in cytokine-cytokine receptor interaction, cell adhesion molecules and phagosome in [Fig. 3D](#f3-or-44-03-0909){ref-type="fig"}. Only the top three terms are listed.

### PPI network

All 106 DEGs from the 2 datasets (GSE114206 and GSE41499) ([Fig. 4A](#f4-or-44-03-0909){ref-type="fig"}) and all 406 DEGs from the 2 datasets (GSE114206 and GSE33482) ([Fig. 4B](#f4-or-44-03-0909){ref-type="fig"}) were analyzed using the STRING database to further examine the characteristics and the potential interconnections of the DEGs. A PPI network of the DEGs was generated in Cytoscape ([Fig. 4A and B](#f4-or-44-03-0909){ref-type="fig"}).

### Protein/gene interaction network and biological processes

GeneMANIA was used to analyze and elucidate the functional roles of NFATc1, KLF4, NR4A3 and HGF in drug tolerance. More importantly, additional bioinformatics analysis exposed the interrelationships among the four genes that play a role in chemotherapeutic resistance in EOC. A protein/gene interaction network was formed for the four genes and 20 genes/proteins that corresponded to drug-tolerance, which included CEBPB, FN1, MET, PTPRJ, MUC20, PPP3CA, PDCD1, NR4A1, NCOR1, GLMN, KLF6, HGFAC, RANBP10, NCOR2, NFATC4, HMGB1, PPP3CC, SIX3, INPPL1 and KDM6B. As shown in [Fig. 5A](#f5-or-44-03-0909){ref-type="fig"}, *NFATc1, KLF4, NR4A3* and *HGF* were associated with 20 drug-resistant proteins/genes.

As shown in [Fig. 5B](#f5-or-44-03-0909){ref-type="fig"}, text mining analysis indicated that these four key genes directly or indirectly participate in 14 physiological processes that contribute to drug-resistance in OC, including cell proliferation, cell differentiation, apoptosis, cell division and phosphorylation (P\<0.05). Additionally, the OncoPrint module in the cBioPortal was used to evaluate genetic conversions and demonstrated that 10% (57/594) of patients exhibited genetic metamorphosis ([Fig. 5C](#f5-or-44-03-0909){ref-type="fig"}).

### RT-qPCR analysis

We quantified the mRNA levels of the four genes *NFATc1, KLF4, NR4A3* and *HGF* in sensitive ovarian cells and cisplatin- and carboplatin-resistant cell lines. The mRNA expression levels of *NFATc1* were significantly increased in cisplatin- and carboplatin-resistant cells compared with those in sensitive OC cells (all P-values \<0.0001; [Fig. 6A-a-c](#f6-or-44-03-0909){ref-type="fig"}). In addition, mRNA expression of *KLF4* was significantly lower in the SKOV3-CDDP and HeyA8-CDDP cell lines than that in the SKOV3 and HeyA8 cell lines (both P\<0.0001; [Fig. 6B-a and -b](#f6-or-44-03-0909){ref-type="fig"}). However, mRNA expression of KLF4 was increased in the A2780-CBP cells (P\<0.0001; [Fig. 6B-c](#f6-or-44-03-0909){ref-type="fig"}). Compared with sensitive cells, the expression of NR4A3 was increased in the SKOV3-CDDP, HeyA8-CDDP and A2780-CBP cells (P\<0.0001, P\<0.01, and P\<0.05, respectively) ([Fig. 6C-a-c](#f6-or-44-03-0909){ref-type="fig"}). We also observed that the expression of HGF was significantly increased in SKOV3-CDDP, HeyA8-CDDP and A2780-CBP cells compared with that in the corresponding sensitive ovarian cancer cells (P\<0.05, P\<0.0001, and P\<0.001, respectively) ([Fig. 6D-a-c](#f6-or-44-03-0909){ref-type="fig"}).

### Cell migration and invasion assay analyses

The migratory and invasive potential of sensitive ovarian cells and cisplatin- and carboplatin-resistant cells in the Transwell migration assay is shown in [Fig. S1A](#SD1-or-44-03-0909){ref-type="supplementary-material"}. Quantification revealed a significant 218.0±8.01% increase in migration in the SKOV3-CDDP cell line compared with that in sensitive SKOV3 cells (P\<0.01; [Fig. S1B-a](#SD1-or-44-03-0909){ref-type="supplementary-material"}), a 169.0±5.15% increase in migration in the HeyA8-CDDP cells compared with that in HeyA8 cells (P\<0.01; [Fig. S1B-b](#SD1-or-44-03-0909){ref-type="supplementary-material"}), and a significant 225.9±14.08% increase in migration in the A2780-CBP cell line compared with that in A2780 cells (P\<0.01; [Fig. S1B-c](#SD1-or-44-03-0909){ref-type="supplementary-material"}). Quantification revealed a significant 216.8±19.52% increase in invasion in the SKOV3-CDDP cell line compared with that in sensitive SKOV3 cells (P\<0.01; [Fig. S1C-a](#SD1-or-44-03-0909){ref-type="supplementary-material"}), a 271.9±22.81% increase in invasion in the HeyA8-CDDP cells compared with that in HeyA8 cells (P\<0.01; [Fig. S1C-b](#SD1-or-44-03-0909){ref-type="supplementary-material"}), and a significant 222.2±6.61% increase in invasion in the A2780-CBP cell line compared with that in A2780 cells (P\<0.01; [Fig. S1C-c](#SD1-or-44-03-0909){ref-type="supplementary-material"}).

Discussion
==========

Ovarian cancer (OC) is the primary cause of death worldwide in female reproductive malignancies ([@b21-or-44-03-0909],[@b22-or-44-03-0909]) OC patients have no apparent symptoms at early stages, and the majority of patients are diagnosed at late stages. The current standard treatment strategy for advanced epithelial ovarian cancer (AEOC) is primary cytoreductive surgery in combination with platinum-based first-line chemotherapy and radiotherapy or endocrine therapy ([@b23-or-44-03-0909],[@b24-or-44-03-0909]). When adequate evaluation suggests that patients are less likely to receive a satisfactory outcome from tumor cell depletion surgery, neoadjuvant chemotherapy (NACT) followed by interval-based nodulation (NACT-IDS) after three platinum-based chemotherapy cycles has become an increasingly common treatment strategy ([@b25-or-44-03-0909]--[@b28-or-44-03-0909]). Overall, research has shown that the survival rate of patients with stage III or IV OC treated with NACT-IDS is not inferior to that of patients receiving primary cytoreductive surgery followed by chemotherapy ([@b27-or-44-03-0909]). However, Rauh-Hain *et al* ([@b5-or-44-03-0909]) suggested that compared with the primary surgery (PDS) group, patients in the NACT-IDS group had a higher rate of resistance to platinum after initial platinum chemotherapy. Therefore, there is an urgent clinical need to identify predictive markers for drug resistance and to accurately assess the risk before treatment to identify AEOC patients who are most likely to benefit from NACT and to optimize the role of NACT in OC treatment.

Therefore, the present study will aid gynecologic oncologists to better understand the mechanisms of OC resistance and avoid the occurrence of early chemotherapy resistance in their patients. Additionally, the core genes in this study may contribute to the identification of candidate biomarkers and the introduction of novel therapeutic targets for EOC.

In our research, the combined analyses identified 4 DEGs between pre-NACT and post-NACT cells that were also in common between sensitive and cisplatin- /carboplatin-resistant OC cells; these genes were ascertained as those most likely to be associated with neoadjuvant chemotherapy and platinum-based chemoresistance in EOC.

The nuclear factor of activated T-cells, cytoplasmic 1 (*NFATc1*) gene is a member of the NFAT gene family and encodes a component of the nuclear factor of activated T cells DNA-binding transcription complex and has been identified as a transcription factor in recent years.

The NFAT family
===============

As required components for promoting and activating the expression of IL-2 and IL-2 receptors, members of the NFAT family are primarily described as being present in inactive T cells and functioning as a set of T cell-specific transcription factors ([@b29-or-44-03-0909]--[@b31-or-44-03-0909]). From the ongoing study of the NFAT family, we have found that NFAT is not only T cell-specific but is also expressed in a wide range of lymphoid cells and possibly in non-lymphocytes, such as natural killer (NK) cells and macrophages. More recently, five *NFAT* subfamily members, including the *NFAT1, NFAT2, NFAT3, NFAT4* and *NFAT5* families, have been discovered ([@b32-or-44-03-0909],[@b33-or-44-03-0909]). Four members of the NFAT gene subfamily, *NFAT1, NFAT2, NFAT3* and *NFAT4*, encode four proteins that are regulated by the calcium and calcineurin signaling pathway. The *NFAT5* gene was found to encode a protein regulated by the cellular response to hyperosmotic stress ([@b34-or-44-03-0909],[@b35-or-44-03-0909]).

Structure of the NFAT family
============================

The general structure of the NFAT protein family is shown in [Fig. 7A](#f7-or-44-03-0909){ref-type="fig"}. The conventional NFAT protein (NFAT1-4) contains N- and C-terminal transactivation domains (TAD-N and TAD-C, respectively), which are highly variable in different NFAT proteins and isoforms. Additionally, except for the absence of a calcineurin-binding domain in the structure of NFAT5, all other conventional members have a Rel homology region (RHR), which consists of an NFAT homology region (NHR) and a DNA-binding domain (DBD). NFAT5 also lacks Fos/Jun residues, so it cannot bind to DNA through c-Fos and Jun. However, NFAT5 preserves the DNA contact residues of NFAT1 through NFAT4, such as the Rel homology domain, which can help bind DNA sequences ([@b36-or-44-03-0909]). Deeper study of the NFAT family has shown that NHR contains several conserved regulatory motifs among NFAT family members, such as a nuclear localization sequence (NLS), a nuclear export signal (NES), serine-rich regions (SRRs), serine-proline repeat motifs (SPs), and a phosphorylation site. Moreover, NFAT family members contain a DNA-binding loop, binding sites for Fos and Jun in NFAT1-4, and a NES in the DNA-binding domain (DBD) ([@b37-or-44-03-0909]). A schematic of the primary alignment of NFAT1-5 is displayed in [Fig. 7B](#f7-or-44-03-0909){ref-type="fig"}.

Function of the NFAT family
===========================

The NFAT family was originally regarded as transcription factors that affect T cell activation. Therefore, in recent decades, members of this family have been major molecular targets for the development of immunosuppressive drugs, such as cyclosporine A, which modulates T cell immunity in autoimmune diseases ([@b38-or-44-03-0909],[@b39-or-44-03-0909]). Accumulating evidence indicates that NFATs are indirectly involved in the regulation of the cell cycle and other processes, which suggests their broader role in normal physiological processes. Participation of NFAT in the processes of tumorigenicity and transformation has been reported ([@b32-or-44-03-0909]). In addition, NFAT proteins can directly regulate the expression of genes related to cellular proliferation, angiogenesis and tissue invasion mechanisms in cancers ([@b40-or-44-03-0909],[@b41-or-44-03-0909]) ([Fig. 7C](#f7-or-44-03-0909){ref-type="fig"}). Xu *et al* ([@b42-or-44-03-0909]) demonstrated that NFATc1 is extremely overexpressed in ovarian tumor tissues compared with normal tissues. Additionally, c-myc was upregulated to accelerate cell proliferation through activation of the ERK1/2/p38/MAPK signaling pathway by NFATc1. Recent research has also found that NFATc1 modulates cell proliferation, migration, and invasion in SKOV3 cells ([@b43-or-44-03-0909]). Additionally, *NFATc1* siRNA can dramatically decrease SKOV3 cell growth ([@b44-or-44-03-0909]). Furthermore, NFATc1 overexpression is linked to a poor prognosis in urothelial carcinoma ([@b45-or-44-03-0909]). NFAT1 also plays a vital role in aspects of drug-resistant cancers. Murray *et al* ([@b46-or-44-03-0909]) demonstrated that NFATc1 is a crucial factor in mediating drug-resistance and upgrades the tumor response to chemotherapeutic drugs in pancreatic cancer. Our research results also demonstrated that the mRNA expression levels of *NFATc1* were significantly increased in cisplatin- and carboplatin-resistant cells compared with those in sensitive OC cells. Thus, our findings in the present study are consistent with the mentioned above studies.

Taken together, the results indicate that NFATc1 may be a drug resistance candidate and that better NFAT inhibitors may be promising targets for neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma. However, more research is needed to further detail the roles of NFATc1 in chemoresistance.

The nuclear receptor subfamily 4 group A member 3 (*NR4A3*) gene, also called the oxidored-nitro domain protein 1 (NOR1), is a member of the NR4A family. NR4A subfamily members are a subfamily of nuclear receptors (NRs).

NRs were identified in metazoans by Mangelsdorf *et al* ([@b47-or-44-03-0909]) and represent the largest family of transcription factors. A number of small lipophilic ligands and cellular signaling pathways, including vitamins, fatty acids and cholesterol metabolites, can regulate a large conserved family of ligand-dependent transcription factors known as NRs ([@b48-or-44-03-0909]). There is increasing evidence that NRs play important roles in a number of human physiological processes, including cell development, reproduction, circadian rhythms, and metabolism, and therefore, they have become primary drug targets for the treatment of cancer, cardiovascular disease and metabolic syndrome ([@b49-or-44-03-0909]--[@b51-or-44-03-0909]). NRs have also been among the most successful targets for drugs approved to treat many diseases, including cancer ([@b52-or-44-03-0909],[@b53-or-44-03-0909]). The 48 members of the NR superfamily of the human genome are divided into seven subfamilies ([@b54-or-44-03-0909],[@b55-or-44-03-0909]). A phylogenetic tree can be used to classify the subfamilies based on their sequences ([@b56-or-44-03-0909]). The seven subfamilies of the 48 NRs are presented in [Fig. 7D](#f7-or-44-03-0909){ref-type="fig"}.

Subfamily 4 consists of neuron-derived orphan receptor-1 (NR4A3), nerve growth factor 1B (NR4A1) and nurr-related factor 1 (NR4A2). A previous study reported that compared with the control myometrium, the expression of NR4A subfamily members was significantly restrained in leiomyoma ([@b57-or-44-03-0909]). In hematopoietic neoplasms, downregulated NRs, NR4A3 and NR4A1, which are believed to be tumor suppressors, were found to contribute to the formation of acute myeloid leukemia ([@b58-or-44-03-0909],[@b59-or-44-03-0909]). In contrast, Haller *et al* ([@b60-or-44-03-0909]) demonstrated that the overexpression of NR4A3 could stimulate cell proliferation in mouse salivary gland cancer. NOR1 may act as an antigen in tumor cells, and altered NOR1 expression can help clarify the function of the NOR1 protein in liver cancer ([@b61-or-44-03-0909]). These results are consistent with our findings indicating that the NR4A3 protein is significantly increased in drug-resistant ovarian cancer. Currently, there are few studies on the *NR4A3* gene and protein in epithelial ovarian tumors. There has been controversy in previous studies regarding the role of the *NR4A3* gene in promoting cancer or tumor suppression in different types of tumors. It is speculated that the detection of altered NOR1 expression before surgery in patients with advanced EOC could help to identify whether tumor cells are resistant to platinum-based chemotherapy drugs. However, the exact function of the *NR4A3* gene and protein has yet to be determined with a sufficient number of validated experimental trials.

KLF4, also known as gut-enriched Krüppel-like factor or GKLF, belongs to the Krüppel transcription factor family and has multiple functions, including cell differentiation, embryogenesis and pluripotency. Shields *et al* ([@b62-or-44-03-0909]) first isolated and identified KLF4 from a NIH3T3 cDNA library. The Human Genome Organization Gene Nomenclature Committee numbered the members of the Krüppel-like factor family in the order in which they were discovered. Based on the structural similarity of their N-terminus, as shown in [Fig. 7E](#f7-or-44-03-0909){ref-type="fig"}, 17 human KLF proteins can be divided into three major subfamilies. Due to the presence of recognizable protein-protein interaction motifs, Krüppel-like factors 5, 15 and 17 are not classified into any other family. The *KLF4* gene is affiliated with the second group of the Krüppel family of transcription factors. Furthermore, group 2 also includes Krüppel-like factors 1, 2, 6 and 7, which are characterized by three zinc fingers in the carboxyl terminus sequences and acidic activation domains and thus generally act as transcriptional activators ([@b63-or-44-03-0909]). The general structure of Krüppel-like factor 4 protein is shown in [Fig. 7F](#f7-or-44-03-0909){ref-type="fig"}.

Recent research has found that KLF4-encoded proteins can induce G1-to-S transition of the cell cycle via the *p53* gene after DNA damage ([@b64-or-44-03-0909]). As a tumor suppressor, it has been documented that overexpression of KLF4 in the human colon cancer cell line RKO can reduce the ability of tumor cells to migrate and invade ([@b65-or-44-03-0909]). By using RT-qPCR technique, we found that mRNA expression of *KLF4* was significantly lower in the SKOV3-CDDP and HeyA8-CDDP cell lines than that noted in the SKOV3 and HeyA8 cell lines in our research. Furthermore, we also observed that the migration and invasion ability of drug-resistant OC cell lines SKOV3-CDDP and HeyA8-CDDP were higher than the SKOV3 and HeyA8 cell lines. Therefore, the results of our study were in line with the above previous experiments. In addition, KLF4 has also been observed to inhibit tumors in lung cancer ([@b66-or-44-03-0909]), cervical cancer ([@b67-or-44-03-0909]), and pancreatic cancer ([@b68-or-44-03-0909]). It is still controversial whether KLF4 plays a role in carcinogenesis ([@b69-or-44-03-0909]) or cancer suppression ([@b70-or-44-03-0909]) in breast cancer. Additionally, it is not fully understood how the *KLF4* gene promotes or suppresses cancer in different tumors. Additionally, KLF4 has a considerable effect on cancer drug resistance. A recent report noted that KLF4 expression was dramatically higher in normal ovarian tissue than in ovarian cancer tissue. However, the efficacy of chemotherapy drugs in OC cells can be significantly improved by small molecule inducers. Thus, the attempt to induce KLF4 expression by APTO-253 is a new therapeutic approach to treat OC and avoid the emergence of chemotherapy resistance ([@b71-or-44-03-0909]). Future studies will be conducted to explore the mechanism of the KLF4 protein in carcinogenesis and chemotherapy resistance.

Mesenchymal cells typically produce a protein knowns as hepatocyte growth factor (HGF) that adheres to the hepatocyte growth factor receptor. This protein regulates cell growth and cell motility in a variety of cells and tissue types.

The HGF receptor and c-Met are highly expressed in some OC cell lines and in epithelial cells of ovarian tumors. Sowter *et al* ([@b72-or-44-03-0909]) demonstrated that the primary cause of OC cell migration may be closely related to HGF in ovarian tumor fluid. Considerable evidence has indicated that HGF/Met is overexpressed in a consistent fraction of OCs ([@b73-or-44-03-0909],[@b74-or-44-03-0909]). Rasola *et al* found that 100 ng/ml exogenous HGF enhanced CDDP- and PTX-induced apoptosis in OC cells via the caspase-dependent apoptosis pathways, and dose-dependent effects were observed ([@b75-or-44-03-0909]). In a comparison of microRNA and gene expression of targets in patients treated with NACT and primary debulking surgery (PDS) followed by platinum/taxane chemotherapy, Mariani *et al* ([@b76-or-44-03-0909]) reported that HGF and its receptor c-Met were notably increased in post-NACT patients. Similarly, the mRNA expression levels of HGF were dramatically increased in cisplatin- and carboplatin-resistant ovarian cancer cell lines. Taken together, these studies explain why the HGF/MET axis has become a candidate target of numerous therapeutic clinical trials in platinum-based chemotherapy resistance in patients with NACT.

PDS in combination with chemotherapy often leads to drug resistance and relapse in advanced OC, and there is a clear need to pursue the development of novel alternative therapies. In the present study, we used NACT as a basis to explore the mechanism underlying drug resistance in combination with sensitive and resistant ovarian cancer cells and to analyze the induction of chemoresistance in tumor cell clone chemotherapy. In conclusion, analysis of the altered expression of NFATc1, NR4A3, KLF3 and HGF as candidate biomarkers will contribute to the selection of patients suitable for this modality of treatment. Furthermore, inhibitors of these targets may improve the therapeutic efficacy of NACT and avoid platinum-based chemotherapy resistance. However, the present study had a limitation. More in-depth experimental studies are necessary to sufficiently confirm the role of these DEGs in drug resistance mechanism of OC.
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![Heat map of the top 400 DEGs. (A-C) The top 200 upregulated DEGs and the top 200 downregulated DEGs in the resistant chemotherapy group compared with the sensitive chemotherapy group. (A) Expression heat map of the top DEGs in GSE114206. (B) Expression heat map of the top DEGs in GSE33482. (C) Expression heat map of the top DEGs in GSE41499. (D) A total of 63 differentially expressed genes were selected as DEGs from GSE109934 profile by comparing the platinum-resistant group with the platinum-sensitive group, and the two groups both contained pre-NACT samples with post-NACT samples, of which 45 upregulated and 18 downregulated genes are shown. Red, upregulated DEGs; blue, downregulated DEGs. DEGs, differentially expressed genes; NACT, neoadjuvant chemotherapy.](OR-44-03-0909-g00){#f1-or-44-03-0909}

![Venn diagram. (A) A total of 106 DEGs in the two datasets (GSE114206 and GSE41499) were singled out, of which 36 genes were upregulated and 70 genes were downregulated. (B) A total of 406 DEGs in the two datasets (GSE114206 and GSE33482) were chosen, of which 157 genes were upregulated and 249 genes were downregulated. (C) Two core genes, NFATc1 and KLF4, were potentially associated with NACT and platinum-based chemoresistance. (D) Three key genes NFATc1, NR4A3 and HGF were selected. (E) The results of the overall screening of the Venn diagram are shown. DEGs, differentially expressed genes; NACT, neoadjuvant chemotherapy; NAFTc1, nuclear factor of activated T-cells, cytoplasmic 1; KLF4, Kruppel-like factor 4; NR4A3, nuclear receptor subfamily 4 group A member 3; HGF, hepatocyte growth factor.](OR-44-03-0909-g01){#f2-or-44-03-0909}

###### 

GO and KEGG pathway analysis of the 106 DEGs and 406 DEGs. (A and B) Barplots were designed by Metascape tool. (C and D) Dotplots were conducted through Easychart tool. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes.
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###### 

PPI network of the DEGs. (A) Gene coexpression network of 106 DEGs from the 2 cohort profile data sets (GSE114206 and GSE41499). (B) Gene coexpression network of 406 DEGs from the 2 cohort profile data sets (GSE114206 and GSE33482). PPI, protein-protein interaction; DEGs, differentially expressed genes.
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###### 

Protein/gene interaction network and biological process annotation of the differentially expressed genes. (A) Protein/gene-protein/gene interaction network of the four proteins/genes with 20 drug resistance-related proteins/genes in OC. (B) Four genes/proteins identified using Coremine Medical tools were associated with drug resistance and OC. Input terms were NFATc1, KLF4, NR4A3, HGF, drug resistance, cisplatin, carboplatin and OC. (C) Genetic alterations. Red indicates amplification and blue indicates deep deletion of genes in 57 of the 594 serous ovarian cancer patients (10%). OC, ovarian cancer; NAFTc1, nuclear factor of activated T-cells, cytoplasmic 1; KLF4, Kruppel-like factor 4; NR4A3, nuclear receptor subfamily 4 group A member 3; HGF, hepatocyte growth factor.
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![Using RT-qPCR to detect gene mRNA expression in cisplatin- and carboplatin-resistant cells and sensitive ovarian cancer cells. (A) NFATc1 mRNA expression level in parental sensitive/resistant: (a) SKOV3/SKOV3-CDDP, (b) HeyA8/HeyA8-CDDP and (c) A2780/A2780-CBP cell lines. (B) KLF4 mRNA expression level in (a) SKOV3/SKOV3-CDDP, (b) HeyA8/HeyA8-CDDP and (c) A2780/A2780-CBP cell lines. (C) NR4A3 mRNA expression level in parental sensitive/resistant: (a) SKOV3/SKOV3-CDDP, (b) HeyA8/HeyA8-CDDP and (c) A2780/A2780-CBP cell lines. (D) KLF4 mRNA expression level in parental sensitive/resistant: (a) SKOV3/SKOV3-CDDP, (b) HeyA8/HeyA8-CDDP and (c) A2780/A2780-CBP cell lines. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001, \*\*\*\*P\<0.0001, compared with the parental cell line. CDDP, cisplatin; CBP, carboplatin.](OR-44-03-0909-g08){#f6-or-44-03-0909}

###### 

\(A\) General structure of the NFAT protein family is shown. NFAT protein consists of N- and C-terminus transactivation domains which are tremendously alterable among the different NFAT members and isoforms. Except that NFAT5 has no calcineurin-binding domain in its structure, all other conventional members have a structure named as REL homology region (RHR), which consisted of a NFAT homology region (NHR) and DNA-binding domain (DBD). (B) Schematic primary alignment of NFAT. The NHR contains a nuclear localization sequence (NLS), a nuclear export signal (NES) and two calcineurin binding sites. NHR also contains serine-rich regions (SRRs), serine-proline-repeat motifs (SPs), and a phosphorylation site, such as casein kinase 1 (CK1), GSK3 docking site. The DNA binding domain, contains DNA-binding loop sites that directly contacts DNA core sequence (A/T) GGAAA and a nuclear localization sequence NLS. C-terminus transactivation domains (TAD-C) consist of two sumoylation sites. (C) Tumor-related processes regulated by NFAT transcription factors. The nuclear factor of activated T-cells (NFAT) family includes five subfamilies, namely, the NFAT1 family, the NFAT2 family and the NFAT3, NFAT4 and NFAT5 family. NFAT proteins directly regulate the expression of genes related to cellular proliferation, apoptosis, angiogenesis and tissue invasion mechanisms among others. (D) NOR1 (NR4A3) belongs to one of the NR4A family. NR4A subfamily members are one of the subfamily of nuclear receptors (NRs). NRs are major drug targets for the therapy of reproductive abnormalities and cancer. We classified and present 48 NR members. (E) Phylogenetic classification of the human Krüppel-like factor (KLF) family. Human Genome Organization Gene Nomenclature Committee has numbered the Krüppel-like factor family in the order in which members of were discovered. Based on the structural similarity of the N-terminal, 17 human KLF proteins can be divided into three major subfamilies. Due to the presence of recognizable protein-protein interactions motifs, KLF5, 15 and 17 are not classified into any other family. KLF3, 8, and 12 (group 1) usually bind to the C-terminal binding proteins (CtBPs), which act as inhibitors of gene transcription. Members of the second group of KLF factors, including 1, 2, 4, 6, and 7, generally reckon as transcriptional activators because they all have acidic activation domains. KLF9, 10, 11, 13, 14 and 16 (group 3) share a Sin3a-interacting domain (SID), an α-helical motif that interworks with the repressor protein Sin3a. (F) Structure and function domains of KLF4, where the amino terminal is the transcriptional activation domain, the carboxyl terminal (triple Cys2-His2 zinc finger) is the DNA-binding domain, which are highly conserved among KLFs, and repression domain is the intermediate target of post-translational regulation.

![](OR-44-03-0909-g09)

![](OR-44-03-0909-g10)

![](OR-44-03-0909-g11)

###### 

Human primer sequences used for real-time quantitative PCR.

  Gene       Forward primer (5′-3′)       Reverse primer (5′-3′)        Annealing temperature (°C)
  ---------- ---------------------------- ----------------------------- ----------------------------
  *NFATc1*   5′-CGATCCCGGGGTAGCAGCCT-3′   5′-CACCGCCATACTGGAGCCGC-3′    62.4
  *KLF4*     5′-TCGGACCACCTCGCCTTACA-3′   5′-CTGGGCTCCTTCCCTCATCG-3′    60.5
  *NR4A3*    5′-GGGAGCCGCTGGGCTTG-3′      5′-CAGTGGGCTTTGAGTGCTGTG-3′   61.0
  *HGF*      5′-TAGGCACTGACTCCGAACA-3′    5′-AGGAGATGCAGGAGGACAT-3′     60.7
  *GAPDH*    5′-CGTGGAAGGACTCATGACCA-3′   5′-GGCAGGGATGATGTTCTGGA-3′    62.0

*NAFTc1*, nuclear factor of activated T-cells, cytoplasmic 1; *KLF4*, Kruppel-like factor 4; *NR4A3*, nuclear receptor subfamily 4 group A member 3; *HGF*, hepatocyte growth factor; *GAPDH*, glyceraldehyde 3-phosphate dehydrogenase.

###### 

Gene Ontology analysis and KEGG enrichment analyses of 106 differentially expressed genes correlated with platinum-based chemoresistance in ovarian carcinoma.

  Category          Term                                                                                  Count   \%    P-value
  ----------------- ------------------------------------------------------------------------------------- ------- ----- ---------
  Upregulated                                                                                                           
    GOTERM_BP_FAT   GO:0009968\~negative regulation of signal transduction                                4       1.2   1.5E-2
    GOTERM_BP_FAT   GO:0010648\~negative regulation of cell communication                                 4       1.2   2.0E-2
    GOTERM_MF_FAT   GO:0030528\~transcription regulator activity                                          8       2.4   2.6E-2
  Downregulated                                                                                                         
    GOTERM_BP_FAT   GO:0031349\~positive regulation of defense response                                   6       0.9   1.9E-5
    GOTERM_BP_FAT   GO:0008285\~negative regulation of cell proliferation                                 10      1.4   3.2E-5
    GOTERM_BP_FAT   GO:0042127\~regulation of cell proliferation                                          14      2.0   3.9E-5
    GOTERM_BP_FAT   GO:0006955\~immune response                                                           12      1.7   2.3E-4
    GOTERM_BP_FAT   GO:0051174\~regulation of phosphorus metabolic process                                10      1.4   3.0E-4
    GOTERM_CC_FAT   GO:0044459\~plasma membrane part                                                      21      3.0   1.5E-3
    GOTERM_CC_FAT   GO:0005886\~plasma membrane                                                           29      4.1   2.7E-3
    GOTERM_CC_FAT   GO:0005576\~extracellular region                                                      19      2.7   3.2E-3
    GOTERM_CC_FAT   GO:0044421\~extracellular region part                                                 11      1.6   1.2E-2
    GOTERM_CC_FAT   GO:0005615\~extracellular space                                                       9       1.3   1.3E-2
    GOTERM_MF_FAT   GO:0005125\~cytokine activity                                                         6       0.9   1.4E-3
    GOTERM_MF_FAT   GO:0008083\~growth factor activity                                                    5       0.7   4.8E-3
    GOTERM_MF_FAT   GO:0005068\~transmembrane receptor protein tyrosine kinase adaptor protein activity   2       0.3   2.1E-2
    GOTERM_MF_FAT   GO:0005539\~glycosaminoglycan binding                                                 4       0.6   2.1E-2
    GOTERM_MF_FAT   GO:0001871\~pattern binding                                                           4       0.6   2.7E-2
    KEGG_PATHWAY    hsa04620: Toll-like receptor signaling pathway                                        4       0.6   2.9E-2

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cell component; MF, molecular function.

###### 

Gene ontology analysis and KEGG enrichment analyses of 406 differentially expressed genes correlated to platinum-based chemoresistance in ovarian carcinoma.

  Category          Term                                                                                                                                    Count   \%    P-value
  ----------------- --------------------------------------------------------------------------------------------------------------------------------------- ------- ----- ---------
  Upregulated                                                                                                                                                             
    GOTERM_BP_FAT   GO:0051240\~positive regulation of multicellular organismal process                                                                     10      0.8   2.7E-4
    GOTERM_BP_FAT   GO:0002474\~antigen processing and presentation of peptide antigen via MHC class I                                                      4       0.3   3.9E-4
    GOTERM_BP_FAT   GO:0048002\~antigen processing and presentation of peptide antigen                                                                      4       0.3   1.8E-3
    GOTERM_BP_FAT   GO:0007267\~cell-cell signaling                                                                                                         14      1.1   2.0E-3
    GOTERM_BP_FAT   GO:0008283\~cell proliferation                                                                                                          11      0.8   4.5E-3
    GOTERM_CC_FAT   GO:0044421\~extracellular region part                                                                                                   26      2.0   1.7E-7
    GOTERM_CC_FAT   GO:0005576\~extracellular region                                                                                                        39      3.0   2.2E-7
    GOTERM_CC_FAT   GO:0044459\~plasma membrane part                                                                                                        39      3.0   2.4E-6
    GOTERM_CC_FAT   GO:0031226\~intrinsic to plasma membrane                                                                                                25      1.9   3.7E-5
    GOTERM_CC_FAT   GO:0005887\~integral to plasma membrane                                                                                                 24      1.8   7.7E-5
    GOTERM_MF_FAT   GO:0005125\~cytokine activity                                                                                                           8       0.6   1.5E-3
    GOTERM_MF_FAT   GO:0030246\~carbohydrate binding                                                                                                        10      0.8   3.5E-3
    GOTERM_MF_FAT   GO:0032393\~MHC class I receptor activity                                                                                               3       0.2   9.2E-3
    GOTERM_MF_FAT   GO:0004947\~bradykinin receptor activity                                                                                                2       0.2   2.6E-2
    GOTERM_MF_FAT   GO:0008454\~alpha-1,3-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity                                              2       0.2   2.6E-2
    KEGG_PATHWAY    hsa04060: Cytokine-cytokine receptor interaction                                                                                        12      0.9   7.3E-5
    KEGG_PATHWAY    hsa04940: Type I diabetes mellitus                                                                                                      5       0.4   9.4E-4
    KEGG_PATHWAY    hsa05330: Allograft rejection                                                                                                           4       0.3   6.3E-3
    KEGG_PATHWAY    hsa05332: Graft-versus-host disease                                                                                                     4       0.3   7.9E-3
    KEGG_PATHWAY    hsa04630: Jak-STAT signaling pathway                                                                                                    6       0.5   2.3E-2
  Downregulated                                                                                                                                                           
    GOTERM_BP_FAT   GO:0050830\~defense response to Gram-positive bacterium                                                                                 5       0.2   1.2E-4
    GOTERM_BP_FAT   GO:0002449\~lymphocyte mediated immunity                                                                                                7       0.3   3.1E-4
    GOTERM_BP_FAT   GO:0002460\~adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains   7       0.3   5.2E-4
    GOTERM_BP_FAT   GO:0002250\~adaptive immune response                                                                                                    7       0.3   5.2E-4
    GOTERM_BP_FAT   GO:0009968\~negative regulation of signal transduction                                                                                  11      0.5   6.9E-4
    GOTERM_CC_FAT   GO:0044421\~extracellular region part                                                                                                   32      1.5   5.2E-6
    GOTERM_CC_FAT   GO:0005615\~extracellular space                                                                                                         23      1.1   1.5E-4
    GOTERM_CC_FAT   GO:0005576\~extracellular region                                                                                                        47      2.2   1.8E-4
    GOTERM_CC_FAT   GO:0044459\~plasma membrane part                                                                                                        46      2.2   2.6E-3
    GOTERM_CC_FAT   GO:0031012\~extracellular matrix                                                                                                        13      0.6   2.7E-3
    GOTERM_MF_FAT   GO:0008081\~phosphoric diester hydrolase activity                                                                                       5       0.2   2.1E-2
    GOTERM_MF_FAT   GO:0005164\~tumor necrosis factor receptor binding                                                                                      3       0.1   2.8E-2
    GOTERM_MF_FAT   GO:0005125\~cytokine activity                                                                                                           7       0.3   3.6E-2
    GOTERM_MF_FAT   GO:0005509\~calcium ion binding                                                                                                         19      0.9   4.0E-2
    GOTERM_MF_FAT   GO:0022890\~inorganic cation transmembrane transporter activity                                                                         6       0.3   4.2E-2
    KEGG_PATHWAY    hsa04514: Cell adhesion molecules (CAMs)                                                                                                8       0.4   6.6E-3
    KEGG_PATHWAY    hsa04060: Cytokine-cytokine receptor interaction                                                                                        11      0.5   1.2E-2
    KEGG_PATHWAY    hsa05330: Allograft rejection                                                                                                           4       0.2   2.2E-2
    KEGG_PATHWAY    hsa04940: Type I diabetes mellitus                                                                                                      4       0.2   3.3E-2
    KEGG_PATHWAY    hsa04672: Intestinal immune network for IgA production                                                                                  4       0.2   4.9E-2

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cell component; MF, molecular function.
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